Gisby J, Beale A S
Chemotherapeutic Research Centre, Beecham Pharmaceuticals Research Division, Betchworth, Surrey, England.
Antimicrob Agents Chemother. 1988 Dec;32(12):1830-3. doi: 10.1128/AAC.32.12.1830.
Amoxicillin-clavulanic acid was compared with ampicillin-sulbactam in preventing the development of mixed infections produced in mice by subcutaneous inoculation of amoxicillin-resistant strains of Bacteroides fragilis and Escherichia coli. At doses designed to produce concentrations in mouse plasma similar to those obtained in humans, both amoxicillin-clavulanic acid and ampicillin-sulbactam were effective in preventing an infection caused by B. fragilis VPI 8908 mixed with E. coli E96, both strains being susceptible in vitro to each combination. However, ampicillin-sulbactam failed to arrest the progression of infections involving a more potent beta-lactamase-producing strain, E. coli 41548, even when a comparatively low inoculum was tested. In contrast, amoxicillin-clavulanic acid therapy effectively reduced the bacterial numbers at the site of infection. These data illustrate the need to treat polymicrobial infections with agents effective against the responsible aerobic as well as anaerobic bacteria.
在通过皮下接种脆弱拟杆菌和大肠杆菌的阿莫西林耐药菌株诱导小鼠产生混合感染方面,对阿莫西林-克拉维酸与氨苄西林-舒巴坦进行了比较。在设计用于使小鼠血浆中浓度与人获得的浓度相似的剂量下,阿莫西林-克拉维酸和氨苄西林-舒巴坦在预防由脆弱拟杆菌VPI 8908与大肠杆菌E96混合引起的感染方面均有效,这两种菌株在体外对每种组合均敏感。然而,即使测试的接种量相对较低,氨苄西林-舒巴坦也未能阻止涉及产β-内酰胺酶能力更强的菌株大肠杆菌41548的感染进展。相比之下,阿莫西林-克拉维酸治疗有效地减少了感染部位的细菌数量。这些数据表明,需要用对需氧菌和厌氧菌均有效的药物治疗多微生物感染。